单克隆免疫球蛋白沉积病肾移植:6例报告
本文报告本机构2010至2019年收治的6例单克隆免疫球蛋白沉积病(MIDD)患者在经含硼替佐米方案及自体干细胞移植(SCT)达到完全血液学缓解后接受肾移植的结局。中位随访20.5个月(自肾移植起)期间,1例血液学复发、2例血液学进展(其中1例移植物MIDD复发),该例接受达雷妥尤单抗单药治疗后达完全血液学缓解但移植物失功;其余5例移植物有功能,中位血肌酐1.68 mg/dL。结果提示对持续完全血液学缓解的MIDD患者可考虑肾移植。
要点
- MIDD患者经含硼替佐米方案联合自体SCT达持续完全血液学缓解后可考虑肾移植。
- 肾移植后仍可出现血液学复发或进展,需监测;移植物MIDD复发可致移植物失功。
- 移植后血液学复发或MIDD复发的最佳治疗策略尚未确定。
核心结论
- 对MIDD且持续完全血液学缓解的患者,可考虑肾移植。
- 肾移植后血液学复发或MIDD复发的最佳治疗方式仍待确定。
研究设计与样本
- 单中心病例系列,纳入2010至2019年间在本机构治疗MIDD后接受肾移植的6例患者。
主要发现
- 所有患者移植前均接受含硼替佐米方案后行大剂量美法仑及自体SCT并达完全血液学缓解,但均维持透析。
- 自肾移植起中位随访20.5个月(自SCT起54个月)期间,1例血液学复发、2例血液学进展(其中1例移植物MIDD复发)。
- 移植物MIDD复发者接受达雷妥尤单抗单药治疗达完全血液学缓解,但移植物失功。
- 其余5例移植物有功能,中位血清肌酐1.68 mg/dL。
临床怎么用
- 对MIDD患者应在达到并维持完全血液学缓解后再评估肾移植可行性。
- 移植后需监测血液学复发及移植物MIDD复发,复发时治疗策略需个体化。
局限性
- 样本量小(6例),为单中心病例报告,结论外推受限。
- 随访时间有限,中位自肾移植起20.5个月。
- 移植后血液学复发或MIDD复发的最佳治疗尚未确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Monoclonal immunoglobulin deposition disease (MIDD) usually leads to kidney failure. Treatment of patients with a bortezomib-based regimen followed by autologous stem cell transplantation (SCT) has been increasingly used, with improvements in the response rates and allograft outcomes in kidney transplant recipients. The objective of this report was to analyze the outcomes of 6 patients who underwent kidney transplantation in our institution after treatment of MIDD between 2010 and 2019. Monoclonal immunoglobulin deposition disease was initially treated with bortezomib-based therapy followed by high-dose melphalan and autologous SCT with complete hematologic response, although all patients remained on dialysis. During a median follow-up of 20.5 months from kidney transplant (54 months from SCT), 1 patient experienced hematologic relapse and 2 had hematologic progression (one of them with MIDD relapse in the allograft) requiring treatment. The patient with organ relapse received daratumumab monotherapy, achieving complete hematologic response but with graft failure. The other 5 patients had functional grafts with median serum creatinine 1.68 mg/dL. These results support that, in patients with MIDD and sustained complete hematologic response, a kidney transplant can be considered. The optimal approach to treatment of hematologic relapse or recurrence of MIDD after kidney transplant remains to be determined.
引用
- Molina-Andújar A, Tovar N, Cuadrado E, et al. Kidney Transplantation in Monoclonal Immunoglobulin Deposition Disease: A Report of 6 Cases. Am J Kidney Dis. 2021. PMID: 33961923. doi:10.1053/j.ajkd.2021.02.337
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。